XOMA Royalty (XOMA) Competitors

Innoviva (NASDAQ:INVA) and XOMA Royalty (NASDAQ:XOMA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

Which has more risk & volatility, INVA or XOMA?

Innoviva has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Comparatively, XOMA Royalty has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.

Is INVA or XOMA more profitable?

XOMA Royalty has a net margin of -13.04% compared to Innoviva's net margin of -16.15%. Innoviva's return on equity of 15.77% beat XOMA Royalty's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	-16.15%	15.77%	8.41%
XOMA Royalty	-13.04%	-12.43%	-4.85%

Which has stronger earnings and valuation, INVA or XOMA?

Innoviva has higher revenue and earnings than XOMA Royalty. XOMA Royalty is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$358.71M	3.40	$23.39M	-$1.01	-19.21
XOMA Royalty	$28.49M	10.97	-$13.82M	-$1.15	-22.70

Do analysts recommend INVA or XOMA?

Innoviva presently has a consensus target price of $55.00, suggesting a potential upside of 183.51%. XOMA Royalty has a consensus target price of $69.50, suggesting a potential upside of 166.18%. Given Innoviva's higher probable upside, analysts plainly believe Innoviva is more favorable than XOMA Royalty.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
XOMA Royalty	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders and institutionals hold more shares of INVA or XOMA?

99.1% of Innoviva shares are held by institutional investors. Comparatively, 95.9% of XOMA Royalty shares are held by institutional investors. 2.3% of Innoviva shares are held by company insiders. Comparatively, 9.1% of XOMA Royalty shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Does the media prefer INVA or XOMA?

In the previous week, XOMA Royalty had 6 more articles in the media than Innoviva. MarketBeat recorded 7 mentions for XOMA Royalty and 1 mentions for Innoviva. Innoviva's average media sentiment score of 0.93 beat XOMA Royalty's score of 0.68 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
XOMA Royalty	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Innoviva beats XOMA Royalty on 9 of the 14 factors compared between the two stocks.